Close Menu

NEW YORK – Roche said Thursday that its diagnostics division revenues grew 2 percent  percent year over year, or 9 percent on a constant exchange rate, in the first nine months of 2020, driven mainly by COVID-19 testing.

For the nine months of 2020, the Basel, Switzerland-based company's total revenues declined 5 percent to CHF 43.98 billion ($48.12 billion) from CHF 46.07 billion during the same period in 2019. At CER, total revenues for the period rose 1 percent.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A 50-year-old cold case was cracked using genetic genealogy, the New York Times reports.

NPR reports that some insect pests are now becoming resistant to Bt crops.

Science reports the US Food and Drug Administration did not consult an outside panel in its approval of remdesivir as a COVID-19 treatment.

In Nature this week: a framework for future human genomic research, PORE-cupine approach to study RNA structure using nanopore sequencing, and more.